Biotech
-
3052CytoDyn’s Preliminary Phase 1b/2 Cancer Results Likely to Receive Breakthrough Therapy Designation (BTD)
CytoDyn Inc. (OTCMKTS: CYDY) announced excellent preliminary results from its Phase 1b/2 clinical trial in metastatic triple negative breast cancer...
-
3681CytoDyn (CYDY) at Crossroads: Past and Current Leadership Collide in Epic Grudgematch
Latest 8-K filing settles dispute for $7.6 million but paves way for Pestell share repurchase at par 13-D Group is outspoken but...
-
344Enzolytics (ENZC) Takes on HIV Heavyweight Gilead Sciences
The cocktail of drugs given to HIV patients has been dominated by Gilead Sciences (GILD) for over a decade. They are the...
-
27714 Biotech Stocks to Watch: AMRN AVXL RGBP SBFM
U.S. biotech stocks are off to a strong start this week. It didn’t take long for investors to get over the Fed’s...
-
324Todos Medical (TOMDF) with a $22 Million Market Cap Taking on Pharma Giant Pfizer for COVID-19 Antiviral
Vaccines have less efficacy with COVID-19 variants Key 3CL protease inhibitors shows promise for any COVID-19 variants, and potentially all coronav...
-
2.5KAikido Pharma’s (AIKI) Clinical Trial Results Continues to Validates Gilead’s $21 Billion Purchase of Immunomedics
Aikido Pharma Inc. (NASDAQ: AIKI) announced excellent phase 1 data at the annual ASCO meeting. The data was presented by Dr. Scott...
-
293Enzolytics (ENZC) Working With Intel (INTC)
Intel whitepaper highlights case study on Enzolytics COVID-19 and HIV potential for neutralization of both viruses. Bear case is nothing but FUD....
-
271CytoDyn FDA Letter is Old News – International Still Progressing
CytoDyn Inc (OTCMKTS: CYDY) shareholders got a real gut check yesterday as the STAT writer Adam Feuerstein sent out a tweet at...
-
5.2KRGBP Stock: Nickel, Dime, Quarter, Dollars
The one OTC stock that needs to be on every investor’s radar right now is Regen BioPharma (OTCMKTS: RGBP). We alerted our...
-
4151Northwest Biotherapeutics Breadcrumbs Point to ASCO Announcement of Top Line Data
For months, shareholders in Northwest Biotherapeutics (OTCMKTS: NWBO) have been speculating on the message boards about the timing of the release o...